---
title: "Pfizer accuses Novo Nordisk of conspiring to evade antitrust scrutiny and \"stifling an emerging comp"
description: "Pfizer accuses Novo Nordisk of conspiring to evade antitrust scrutiny and \"stifling an emerging competitor\" by sabotaging Pfizer's deal with Metsera"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263812248.md"
published_at: "2025-10-31T21:54:00.000Z"
---

# Pfizer accuses Novo Nordisk of conspiring to evade antitrust scrutiny and "stifling an emerging comp

> Pfizer accuses Novo Nordisk of conspiring to evade antitrust scrutiny and "stifling an emerging competitor" by sabotaging Pfizer's deal with Metsera

Pfizer accuses Novo Nordisk of conspiring to evade antitrust scrutiny and "stifling an emerging competitor" by sabotaging Pfizer's deal with Metsera

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)
- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novo Nordisk A/S - share repurchase programme | Novo Nordisk A/S has initiated a share repurchase programme of up to DKK 15 billion, starting from 4 February 2026. As o | [Link](https://longbridge.com/en/news/276056741.md) |
| Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study | Pfizer Inc. (PFE) is launching a new observational study in Taiwan to evaluate the effectiveness of its multiple myeloma | [Link](https://longbridge.com/en/news/276252273.md) |
| GLP-1 Anti-Obesity U.S. Drug Market In Four Charts | UBS analysts, led by Matthew Weston, have analyzed trends in the U.S. GLP-1 anti-obesity drug market, focusing on new-to | [Link](https://longbridge.com/en/news/276280378.md) |
| Novo Nordisk: Will Have Replacements for Ozempic and Wegovy Ready When Patents Expire - Berlingske | Danish pharmaceutical company Novo Nordisk plans to have replacement drugs ready for Ozempic and Wegovy when their paten | [Link](https://longbridge.com/en/news/276314777.md) |
| Novo Nordisk Gets European Commission Approval for Higher-Dose Wegovy Injectable | 09:25 AM EST, 02/17/2026 (MT Newswires) -- Novo Nordisk ( NVO ) said Tuesday the European Commission has approved a 7.2  | [Link](https://longbridge.com/en/news/276138110.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.